255064-10-9

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-4-methyl-1H-benzimidazole is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of anti-cancer and anti-inflammatory drugs. Its unique structure allows for the creation of molecules with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Bromo-4-methyl-1H-benzimidazole is utilized as a precursor in the production of fungicides and pesticides, capitalizing on its potential to combat a range of agricultural pests and diseases.
Used as a Fluorescent Probe in Biological Imaging:
6-Bromo-4-methyl-1H-benzimidazole has been researched for its application as a fluorescent probe, which can be instrumental in biological imaging. Its fluorescent properties allow it to be used for detecting and visualizing specific biological processes or structures within living organisms.
Used as an Inhibitor of Protein Kinases:
Additionally, 6-BROMO-4-METHYL-1H-BENZOIMIDAZOLE has been explored for its potential as an inhibitor of protein kinases, which are crucial in various cellular functions. Its ability to modulate kinase activity can have implications in the treatment of diseases where kinase dysregulation is a factor.
Overall, 6-Bromo-4-methyl-1H-benzimidazole is a multifaceted chemical with applications that span from therapeutic development to research tools, highlighting its importance in both medical and scientific domains.

InChI:InChI=1/C8H7BrN2/c1-5-2-6(9)3-7-8(5)11-4-10-7/h2-4H,1H3,(H,10,11)

Upstream product

• 64-18-6 formic acid 
• 76153-06-5 5-bromo-3-methylbenzene-1,2-diamine 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 4887-83-6 4-methylbenzimidazole 
• 255064-08-5 6-bromo-1H-benzo[d]imidazole-4-carboxylic acid 
• 952511-71-6 7-methyl-1H-benzimidazole-5-carbonitrile 
• 398452-96-5 4-methyl-1H-benzo[d]imidazole-6-carboxylic acid 
• 255064-05-2 6-bromo-7-nitro-1H-benzoimidazole-4-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide 

Relevant academic research and scientific papers

FUSED IMIDAZOLE COMPOUNDS

The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase

This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.

OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS

The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases.

Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT3 receptors

A new series of azabicyclic benzimidazole-4-carboxamides 2-21 and - carboxylates 22-30 were synthesized and evaluated for binding affinity at serotoninergic 5-HT3 and 5-HT4 receptors in the CNS. Most of the synthesized compounds exhibited high or very high affinity for the 5-HT3 binding site and low to no significant affinity for the 5-HT4 receptor. SAR observations indicated that a halogen atom at the 6-position and a nitro group at the 7-position of the benzimidazole ring is the best substitution pattern for 5-HT3 affinity and 5-HT3/5-HT4 selectivity, as well as no substitution in this ring. (S)-(-)-N-(Quinuclidin-3-yl)benzimidazole-4- carboxamides 2, 8, and 14 bound at central 5-HT3 sites with high affinity (K(i) = 2.6, 0.13, and 1.7 nM, respectively) and excellent selectivity over serotonin 5-HT4 and 5-HT(1A) receptors (K(i) > 1000-10000 nM). Furthermore, these new 5-HT3 receptor ligands were pharmacologically characterized as potent and selective 5-HT3 antagonists in the isolated guinea pig ileum (pA2 = 9.6, 9.9, and 9.1, respectively).